Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals宣佈向新的現有投資者出售總額爲110萬美元的優先股；它爲推動Navidea的 NAV3-32 和 NAV3-33 試驗接近完成提供額外資金
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals宣佈向新的現有投資者出售總額爲110萬美元的優先股；它爲推動Navidea的 NAV3-32 和 NAV3-33 試驗接近完成提供額外資金